Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

J. Sandborn, William; G. Feagan, Brian; Rutgeerts, Paul; B. Hanauer, Stephen; Colombel, Jean‐Frédéric; E. Sands, Bruce; Lukáš, Milan; N. Fedorak, Richard; Lee, Scott; Bressler, Brian; H. Fox, Irving; Rosario, Maria; Sankoh, Serap; Xu, Jing; Stephens, Kristin; Milch, Catherine; Parikh, Asit

doi:10.1056/nejmoa1215739

Public

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Published in New England Journal of Medicine • Aug 21, 2013

Authors:

William J. Sandborn

Brian G. Feagan

Paul Rutgeerts

Abstract

BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 p...

Subject

Vedolizumab

Maintenance therapy

Crohn's disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!